Diagnostic Testing for Porphyria
A random spot urine sample measuring porphobilinogen (PBG), δ-aminolevulinic acid (ALA), and creatinine is the key confirmatory test for acute hepatic porphyria, with both PBG and ALA typically elevated at least 5-fold (often >10-fold) above normal during acute attacks. 1, 2
First-Line Biochemical Testing
For Acute Porphyrias (Neurovisceral Symptoms)
Collect a single random (spot) urine sample—preferably morning urine—and measure PBG, ALA, and creatinine simultaneously. 1, 2 This is the American Gastroenterological Association's recommended first-line test.
Never use 24-hour urine collections, as the elevations during acute attacks are sufficiently high that a random sample is adequate and avoids delays. 2
PBG is the most specific marker: levels >10 times the upper limit of normal (>10 μmol/mmol creatinine) confirm an acute porphyria attack with high certainty. 2
Both ALA and PBG must be measured together because ALA alone is less specific and can be elevated in lead poisoning and hereditary tyrosinemia. 1, 2
If both ALA and PBG are normal during symptoms, acute hepatic porphyria is effectively ruled out (with the rare exception of ALAD deficiency porphyria where only ALA is elevated). 2, 3
For Cutaneous Porphyrias (Skin Symptoms)
Obtain an EDTA blood sample for plasma porphyrin fluorescence emission spectroscopy and a random urine sample for total urine porphyrins (TUP). 4
Whole blood porphyrin analysis is essential to identify erythropoietic protoporphyria. 4
Plasma fluorescence scanning is more sensitive than fecal porphyrin analysis for variegate porphyria, with sensitivity of 0.96 versus 0.77 in adults. 5
Critical Diagnostic Pitfalls to Avoid
Never use urine porphyrins alone as a screening test—this is the most common diagnostic error, as mild nondiagnostic elevations can be incorrectly interpreted as indicating acute hepatic porphyria. 2, 4
Do not rely on qualitative tests (Watson-Schwartz or Hoesch tests) alone; always use quantitative ALA and PBG measurements for definitive diagnosis. 2, 6
Hemin treatment can lower or normalize PBG excretion if sampling occurs during or shortly after treatment, potentially causing false-negative results. 2
Dilute urine samples may lead to false-negative results if not normalized to creatinine; repeat testing if urine creatinine is <2 mmol/L. 4
Confirmatory Genetic Testing
Once biochemical testing confirms elevated ALA and PBG (≥5-fold above normal), genetic testing by sequencing ALAD, HMBS, CPOX, and PPOX genes is mandatory to confirm the diagnosis and identify the specific type of acute hepatic porphyria. 1, 7
Genetic testing should never be used as first-line screening (except in Scandinavian populations with founder mutations) because most carriers of pathogenic variants never develop symptoms. 2, 7
Whole-gene sequencing can identify 95-99% of cases and is the gold standard for confirmation. 7
First-degree family members require genetic screening once the pathogenic variant is identified in the proband. 7
Diagnostic Interpretation Algorithm
When PBG and ALA are both elevated ≥5-fold:
- Proceed to genetic testing to determine specific type (AIP, VP, HCP, or ALAD porphyria). 1, 7
- Examine sun-exposed skin for chronic cutaneous blistering, which occurs in VP but not in AIP or HCP. 7
When only ALA is elevated:
- Check lead levels and urine organic acids to rule out lead poisoning and hereditary tyrosinemia. 1, 3
- Consider rare ALAD deficiency porphyria. 1, 8
When PBG is at the upper limit of normal during ongoing symptoms:
- This is not consistent with an acute porphyria attack; consider alternative diagnoses. 3
Timing and Sample Handling
Testing is most informative when performed during symptomatic episodes, as PBG and ALA are highest during acute attacks. 1, 4
In patients with recurrent acute attacks, ALA and PBG typically remain elevated even at baseline between attacks. 2
Protect all samples from light and refrigerate or freeze promptly to prevent degradation. 3, 4
Modern LC-MS/MS methods provide high sensitivity and specificity, though results often require 1-2 weeks from reference laboratories. 2
Clinical Context for Testing
Consider acute hepatic porphyria in any patient—especially women aged 15-50 years—presenting with unexplained recurrent severe abdominal pain, as diagnosis is frequently delayed by an average of 15 years from symptom onset. 1, 2
Clinical features alone are not specific enough to establish a porphyria diagnosis; biochemical confirmation is essential. 1
Secondary abnormalities of porphyrin accumulation and excretion occur in many other disorders that are collectively far more common than the porphyrias, making proper interpretation crucial. 1